BioCryst Pharma (BCRX) Reports FDA Approval of ORLADEYO (berotralstat)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
December 3, 2020 8:45 PM ESTSignificant and sustained reduction in HAE attacks
Oral, once-daily prophylactic option enables HAE patients to reduce burden of therapy1Â
ORLADEYO approved for adult and pediatric patients 12 years and older
RESEARCH TRIANGLE PARK, N.C., Dec.... More
